Oppenheimer: These 3 stocks can increase over 80%
The best companies on Wall Street look not only at stocks, but also at the big picture. And Oppenheimer’s chief investment strategist, John Stolzfuss, was especially good at showing us macro vision. In its first note of the new year, Stoltzfus noted a number of factors that will affect the markets. The big news, of course, the 800-kilogram gorilla, which cannot be ignored, is the ongoing epidemic of COVID. The disease is making a strong comeback now that we have entered the winter ̵
1; which was somewhat expected, as it is typical behavior for flu-like respiratory viruses. With the wave of viruses in the winter, we also have to fight a new set of locking policies imposed by state or local levels. We hope that the new vaccines available against COVID will begin to reduce the new coronavirus by spring. “The time that households and economies have been negatively affected by the spread of the virus around the world is likely to lead to less resistance to inoculation against Covid-19 than many experts feared at the start of the pandemic. We expect stock markets. to remain sensitive to the pandemic developments that have held the United States and the global economy hostage for almost a year, “The second-largest news, but most likely, according to Stolzfuss, to impress the market, is the Georgian election. Both Democratic candidates won seats in the Senate, giving Biden’s incoming administration the ability to push policies through Congress over any opposition – for at least the next two years. This victory of the Democrats, providing short-term one-party control of the presidency and Congress, has Stolzfuss worried. In his campaign, Joe Biden promised to repeal Trump’s tax policy and take a number of major spending initiatives. If he continues now, Biden’s policy is likely to increase both taxes and federal spending. And according to Stolzfuss, this will probably cost the markets; Stoltzfus believes that unlimited progressive / democratic policies will leave the S&P 500 vulnerable to losses in the range of 6% to 10%. Before embarking on sales, Oppenheimer’s business analysts remind investors that convincing opportunities can still be found. The company’s analysts have marked three shares, which they say will increase by 80% next year. Using the TipRanks database, we learned that the rest of the street agrees, as all three are proud of the Strong Purchase analysts’ consensus. miRagen Therapeutics (MGEN) miRagen Therapeutics aims to develop new treatment options for diseases that today’s therapies cannot adequately improve. The company’s leading drug candidate is VRDN-001, an anti-IGF-1R monoclonal antibody in clinical trials such as the treatment of ocular thyroid disease (TED). miRagen acquired the rights to VRDN-001 late last year, following its acquisition of Veridian Therapeutics in October. The monoclonal antibody is about to enter phase 2 of a clinical trial, with initial results expected around mid-2021. miRagen is funding its current research with a $ 91 million capital raising agreed in a private placement funding agreement. With this agreement in place, miRagen ended the third quarter with $ 144 million in cash, but more importantly, a clear money lane extends to 2023. Among the bulls is Oppenheimer analyst Leland Gershell, who rates MGEN as better. (ie Buy), along with a price tag of $ 37. This figure shows room for 102% one-year growth. (To watch Gershell’s record, click here) Supporting his position, Gershell says: “The recent acquisition of Viridian and the $ 91 million fundraiser have set miRagen a new course as incoming programs position it to compete in the fertile disease market. of the thyroid gland … we see great revenue potential for [VRDN-001], and its higher power can allow for differentiation … We expect that progress in the development of MGEN’s TED candidates will support excellence. “Overall, Wall Street likes the risk / reward factor, as TipRanks demonstrates a strong consensus that inspires MGEN’s success. The shares are selling for $ 18.26 and have an average price price of $ 32. This goal implies a 75% increase compared to current levels. (See MGEN stock analysis for TipRanks) Oric Pharmaceuticals (ORIC) The success of the pharmaceutical industry, ironically, has posed a significant challenge: many diseases are becoming resistant to existing therapies. Many cancers are among the diseases subject to resistance and subsequent recurrence, serious problems that both affect the patient’s quality of life and increase mortality. Oric Pharmaceuticals, a biopharmaceutical clinical research company, is working on treatment to overcome resistance to cancer. The main candidate for ORIC-101 is ORIC-101, which shows promise as a glucocorticoid receptor (GR) antagonist. The drug is in two separate phase 1b studies, one for prostate cancer and one for solid tumors. Modern drug research is expensive, and Oric recently raised capital through a successful public offering of shares. The company released more than 5.79 million new shares in November, at $ 23 each, and raised more than $ 133.3 million. Oppenheimer’s 5-star analyst, Kevin DeGitter, covers Oric and he’s a bull. DeGeeter supports its superiority rating (ie purchase) with a price tag of $ 62, which implies a one-year potential for an increase of 88%. (To view DeGeeter’s record, click here) In support of his optimistic stance, DeGeeter writes: “We view ORIC as an investment in a management team with a previous history of successfully developing clinically important cancer drugs. Our dissertation suggests … clinical data supporting best-in-class ORIC-101 profile based on either ease of use or superior efficacy in a selected population of biomarkers. We believe that current investor expectations add significant value to ORIC-101’s potential best-in-class profile and management skills. “Overall, ORIC shares gained unanimous thumbs from analysts’ consensus, with 3 recent purchase reviews adding a strong buy rating. The stock is priced at $ 32.91, while the average price of $ 50.67 shows room for growth from ~ 54%. (See TipRanks ORIC inventory analysis) Triterras (TRIT) Following is a billion-dollar unicorn fintech startup that has been on the public market for less than three months.Triterras provides an online trading and financing platform. trade, Kratos, based on blockchain technology.The trade financing or provision of credit services in the physical transport of market goods amounts to about $ 40 billion a year; the Triterras platform uses the secure nature of the blockchain as a point of sale for online merchants. merger of SPAC, ie a business combination with a special acquisition company, these companies exist to acquire a target company, raising capital and then placing the merged entity on public markets. Regarding the current status of the company, he writes, “… the results and momentum seem strong, and the year-round guidelines assume 235% and 142% annual growth of revenues and net income on a low basis. More importantly, while the company is growing faster than other high-growth markets, stocks are trading at a discount on average to low-growing markets. Lau was finally excited, saying, “We see an intriguing paper-and-electronic capability in Triterras that uses blockchain technology to disrupt the low-tech perception in the trading and trade finance industry. According to these comments, Lau estimates TRIT with a better result (ie purchase), and its goal of $ 23 implies 93% growth for the coming year. (To watch Lau’s record, click here) Overall, this company has 3 recent reviews and they all need to buy, which makes the consensus of Strong Buy analyst unanimously positive. The shares are priced at $ 10.94 with an average price target of $ 19, which gives the shares ~ 60% one-year potential for increase. (See an analysis of TRIT shares in TipRanks.) To find good ideas for trading stocks at attractive ratings, visit TipRanks’ Best Buy Shares, a newly created tool that brings together all insights into TipRanks ownership. Disclaimer: The views expressed in this article are those of the analysts submitted. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.